v3.24.1.1.u2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:    
Research and development, net of grants $ 3,726 $ 3,955
General and administrative, net of grants 2,501 2,646
Total operating expenses 6,227 6,601
Loss from operations (6,227) (6,601)
Other income, net 188 283
Net loss $ (6,039) $ (6,318)
Net loss per common share - basic and diluted (0.12) (0.12)
Weighted average common shares outstanding - basic and diluted 52,202 50,755

Source